Company intelligence / Profile preview
Sandoz
Rotkreuz/Risch ZG, Zug, Switzerlandsandoz.com ↗
- Ownership
- Public · SDZ
- Employees
- ~23000
- Development stage
- Commercial
01
Overview
Sandoz is one of the world’s largest producers of generic pharmaceuticals and biosimilars. The company has a long history dating back to its founding in Switzerland in the late nineteenth century. It was part of Novartis from the late '90s until spinning out as an independent entity in October 2023. Today it operates globally with a broad portfolio covering small molecule generics and complex biologic medicines such as biosimilars. Recent clinical/commercial highlights include acquiring CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences and entering into agreements to commercialize new biosimilar products like SB17 ustekinumab.
- Therapeutic areas
- Other
- Modalities
- Small moleculesBiosimilars/biologics
- Industry
- Biotech
02
Drug pipeline
46 assets45 more assets in the full pipeline.
Request access →03
Partnerships
Samsung Bioepis for commercialization rights to SB17 ustekinumab in Europe/North America; various global supply/distribution partnerships.
04
Financials
- Market cap
- $30.7M
- Total revenue
- $21M
Beyond the preview
Go deeper on Sandoz.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sandoz.